Compare Ginkgo Bioworks Holdings Inc (DNA) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Marqeta Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.3 (market cap $505.73M), while Marqeta Inc trades at $15.69 (market cap $1.62B). The key difference: Marqeta Inc is far larger — about 3.2× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| DNA | MQ | |
|---|---|---|
Market Cap | $505.73M | $1.62B |
Sector | Health | Technology |
52-Week High | $16.14 | $26.00 |
52-Week Low | $5.48 | $15.04 |
Enterprise Value | $607.68M | $935.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Marqeta (MQ) trades at $15.62, up 0.13% with a bearish technical outlook. The company shows improving fundamentals with Q2 2026 revenue growth of 17% and second consecutive GAAP profitability. Recent partnerships with Google and Riskified highlight strategic expansion, while a 4:1 reverse stock split was completed in July 2026. Valuation remains elevated with a P/E of 173, though analyst consensus targets $19.00 with 32% buy ratings.
The outlook suggests cautious optimism as Marqeta transitions to profitability amid competitive fintech pressures. Key risks include execution on new initiatives and maintaining growth momentum. Upside potential exists if recent partnerships drive sustained revenue acceleration, but high valuation multiples require continued strong performance to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
